RxDoctor Payments Data

Johanna Schuessler, PA

Medical · Saint Louis, MONPI 1871612309

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations.

$1,409in general payments, 2019–2025

Across 82 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$269
  • Novo Nordisk$194
  • Pfizer$139
  • Astellas Pharma US Inc$113
  • Johnson & Johnson$85
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$83
  • plus $526 from 16 others

What the payments were for

  • Food & beverage$1,409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,409 in reported general payments places this provider in the 70th percentile of 198 medical providers in Missouri.

See all medical providers in Missouri

Medicare billing

Part B allowed, 2024
$15,519
Medicare patients
90
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$20,732
Tresiba Flextouch U-100Insulin Degludec13$6,566
Atorvastatin Calcium60$431
Pantoprazole Sodium16$393
Omeprazole26$356
LevoxylLevothyroxine Sodium11$326
Gabapentin11$245
Montelukast Sodium18$237
Hydrochlorothiazide17$161
Rosuvastatin Calcium22$122
Amlodipine Besylate33$88
Losartan Potassium20$81
Ezetimibe18$80
Lisinopril21$77
Levothyroxine Sodium16$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Levoxyl$139$21,05724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 198 medical providers in Missouri.

Other medical in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →